Write your message
Volume 3, Issue 2 (Spring 2018)                   J Obstet Gynecol Cancer Res 2018, 3(2): 53-58 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Osmani F, Hajizadeh E, Rasekhi A A. Joint Frailty Modeling for Multiple Recurrent Events and Its Application in Patients with Breast Cancer. J Obstet Gynecol Cancer Res. 2018; 3 (2) :53-58
URL: http://jogcr.com/article-1-195-en.html
1- Biostatistics Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran
2- Biostatistics Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran , hajizadeh@modares.ac.ir
Abstract:   (1580 Views)
Aims: Breast cancer is one of the most prevalent recurrent cancers among women. Several factors affecting multiple recurrences of this disease have been studied and recognized in various studies. One of the various types of models used to analyze recurrent events considering the lack of homogeneity among patients is a frailty model. The aim of the present study was to investigate joint frailty modeling for multiple recurrent events and its application in patients with breast cancer.
Materials and Methods: In this survival and retrospective analysis, 342 patients with breast cancer whose records were registered for follow-up in a Cancer Research Center at Shohadaye Tajrish Hospital, Tehran, Iran, from 2006 to 2015, were selected. The sampling method was purposive. These patients were monitored for at least 6 months after diagnosis and their latest statuses. For data analysis, the joint frailty survival model was used. Running the model and conducting the data analysis were performed by codes in Frailtypack using R 3.4.1 statistical software.
Findings: Three-year and five-year survival rates for the patients were 0.79 and 0.68, respectively. The risk of multiple recurrences (Local and metastases) increased for the patients with tumor grades greater than I. It was found that when neglecting the relationship between multiple recurrences in the patients with breast cancer, a significant correlation was missed.
Conclusion: With regard to the significant variance of the frailty component of the metastases event, the patients with the same predictive variables are prone to different levels of metastases risk.
Full-Text [PDF 464 kb]   (892 Downloads)    
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2018/12/26 | Accepted: 2018/12/26 | Published: 2018/12/26

References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6. [DOI:10.1002/ijc.1440] [PMID]
2. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: Results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24-7.
3. Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009;16(3):703-13. [DOI:10.1677/ERC-09-0012] [PMID] [PMCID]
4. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin cancer res. 2005;11(11):4083-9. [DOI:10.1158/1078-0432.CCR-04-2191] [PMID]
5. Uría JA, Ståhle-Bäckdahl M, Seiki M, Fueyo A, López-Otín C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res. 1997;57(21):4882-8.
6. Lentzsch S, Reichardt P, Weber F, Budach V, Dörken B. Brain metastases in breast cancer: Prognostic factors and management. Eur J Cancer. 1999;35(4):580-5. [DOI:10.1016/S0959-8049(98)00421-3]
7. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nat. 1986;320(6058):134. [DOI:10.1038/320134a0] [PMID]
8. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21(6):1254-61. [DOI:10.1093/annonc/mdp427] [PMID]
9. Cook RJ, Lawless JF. Analysis of repeated events. Stat Methods Med Res. 2002;11(2):141-66. [DOI:10.1191/0962280202sm278ra] [PMID]
10. Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics. 2004;60(3):747-56. [DOI:10.1111/j.0006-341X.2004.00225.x] [PMID]
11. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68(2):373-9. [DOI:10.1093/biomet/68.2.373]
12. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84(408):1065-73. [DOI:10.1080/01621459.1989.10478873]
13. Mansouri P, Hajizadeh E, Osmani F. Analysis of risk factors for psoriasis recurrence using proportional rates model. J Skin Stem Cell. 2014;1(3):e25808. [DOI:10.17795/jssc25808]
14. Spiekerman CF, Lin DY. Marginal regression models for multivariate failure time data. J Am Stat Assoc. 1998;93(443):1164-75. [DOI:10.1080/01621459.1998.10473777]
15. Aalen O, Borgan O, Gjessing H. Survival and event history analysis: A process point of view. New York: Springer-Verlag; 2008. [DOI:10.1007/978-0-387-68560-1]
16. Osmani F, Hajizadeh E, Mansoori P. Estimation of seasonal effect on the psoriasis recurrence using time dependent coefficient rates model for recurrent events. J Dermatol Cosmet. 2015;6(1):23-30. [Persian]
17. Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028-37. [DOI:10.1200/JCO.2005.04.3273] [PMID]
18. Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, Brouste V, Soubeyran P. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: Application on cancer events. Biostatistices. 2007;8(4):708-21. [DOI:10.1093/biostatistics/kxl043] [PMID]
19. Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A, Barinoff J, et al. Cerebral metastases in metastatic breast cancer: Disease-specific risk factors and survival. Ann Oncol. 2011;22(7):1571-81. [DOI:10.1093/annonc/mdq625] [PMID]
20. Vahdaninia M, Montazeri A. Breast cancer in Iran: A survival analysis. Asian Pac J Cancer Prev. 2004;5(2):223-5.
21. Gohari MR, Mahmoudi M, Mohammed K, Pasha E, Khodabakhshi R. Recurrence in breast cancer, analysis with frailty model. Saudi Med J. 2006;27(8):1187-93.
22. Mirzaei HR, Hajian S, Mofid B. The role of prognostic factors on breast cancer recurrence in patients at radiation oncology ward in Imam Hossain hospital. Iran J Breast Dis. 2008;1(2)18-23. [Persian]
23. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242-8. [DOI:10.1093/annonc/mdn036] [PMID]
24. Rondeau V, Mathoulin-Pélissier S, Tanneau L, Sasco AJ, Mac Grogan G, Debled M. Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: Recurrence, metastases, second cancer and death. BMC Cancer. 2010;10:697. [DOI:10.1186/1471-2407-10-697] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.